drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells engineered ex vivo to express a chimeric antigen receptor that recognizes CD70, activating T-cell cytotoxicity to eliminate CD70-positive lymphoma cells.
nci_thesaurus_concept_id
C201176
nci_thesaurus_definition
Any preparation of chimeric antigen receptor (CAR) expressing T-lymphocytes that targets the tumor-associated antigen (TAA) CD70.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express a chimeric antigen receptor that recognizes CD70 on tumor cells. Binding to CD70 triggers CAR signaling (CD3zeta with costimulatory domains), activating and expanding the T cells to release cytotoxic molecules and cytokines, thereby killing CD70-positive lymphoma cells independent of MHC presentation.
drug_name
CD70-targeting CAR-T cells
nct_id_drug_ref
NCT05948033